Skip to main content
Bliss GVS Pharma Limited logo

Bliss GVS Pharma Limited — Investor Relations & Filings

Ticker · BLISSGVS ISIN · INE416D01022 LEI · 335800GXY3YCGGP7KJ45 BSE.NS Manufacturing
Open in API
Filings indexed 1,237 across all filing types
Latest filing 2025-04-15 Regulatory Filings
Country IN India
Listing BSE.NS BLISSGVS

About Bliss GVS Pharma Limited

https://blissgvs.com/

Bliss GVS Pharma Limited specializes in the development, manufacturing, and marketing of diverse pharmaceutical formulations. The company is a global leader in the production of suppositories and pessaries, maintaining an extensive portfolio within these specialized dosage forms. Its therapeutic focus includes anti-malarials, anti-fungals, anti-bacterials, anti-inflammatories, and gastrointestinal treatments. The organization operates state-of-the-art manufacturing facilities compliant with international quality standards, including WHO-GMP. With a strategic focus on emerging markets, the company distributes its range of prescription and over-the-counter products across Sub-Saharan Africa, Southeast Asia, and Latin America, leveraging a robust supply chain to provide accessible healthcare solutions.

Recent filings

Filing Released Lang Actions
Pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015, we would like to inform you that the Rising Pharma Holdings, Inc. USA, a marketing and distribution partner of bliss GVS Pharma ....
Regulatory Filings Classification · 95% confidence The document is a formal notification addressed to stock exchanges under Regulation 30 of SEBI (LODR) Regulations, 2015, which pertains to disclosure of material events. The content informs about the USFDA approval of a product by the company's marketing partner. There are no financial statements, detailed financial analysis, or comprehensive report content. The document is short (1953 characters) and serves as an announcement of a material event rather than a full report or detailed filing. This fits the category of a Regulatory Filing (RNS), which covers general regulatory announcements and compliance disclosures that do not fit other specific categories.
2025-04-15 English
Updates
Regulatory Filings Classification · 95% confidence The document is a formal notification addressed to stock exchanges under Regulation 30 of SEBI (LODR) Regulations, 2015, which pertains to disclosure of material events. The content informs about the USFDA approval of a product by the company's marketing partner. There are no financial statements, detailed financial analysis, or comprehensive report content. The document is short (1953 characters) and serves as an announcement of a material event rather than a full report or detailed filing. It does not fit categories like Annual Report, Earnings Release, or Management Reports. It is a regulatory announcement about a significant business development, thus best classified under Regulatory Filings (RNS).
2025-04-15 English
This is a continuation of our communication dated March 26, 2021, regarding the commercial suit for infringement of Intellectual Property Rights. We previously informed you that Bliss GVS ....
Legal Proceedings Report Classification · 95% confidence The document is a formal communication addressed to stock exchanges (NSE and BSE) regarding a legal matter, specifically a court judgment on a commercial suit for infringement of intellectual property rights. It details the court's decision, relief granted, and dismissal of the defendant's counterclaim. There is no financial data, no mention of financial results, no report attached or referenced, and no indication of management or board changes. The content is clearly about a legal proceeding update. According to the filing definitions, this fits best under Legal Proceedings Report (LTR). The document length is short and focused solely on legal information, confirming it is not a report publication or regulatory filing. Therefore, the classification is LTR with high confidence.
2025-04-12 English
Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company
Legal Proceedings Report Classification · 100% confidence The document is a formal communication addressed to stock exchanges (NSE and BSE) regarding a legal matter, specifically a court judgment on a commercial suit for infringement of intellectual property rights. It details the outcome of the lawsuit, including reliefs granted by the court. There is no financial data, no mention of financial results, no management discussion of financial performance, no voting results, no capital changes, and no regulatory certifications. The content is clearly about a legal proceeding update. Therefore, the document fits best under the category of Legal Proceedings Report (LTR). The document length is short and it is not an announcement of a report publication but a substantive update on a legal matter.
2025-04-12 English
Please find attached herewith a certificate received from MUFG Intime India Private Limited, Registrar and Share Transfer Agent of the Company under Regulation 74(5) of the Securities Exchange ....
Regulatory Filings Classification · 95% confidence The document is a certificate under Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018, for the quarter ended March 31, 2025. It is addressed to stock exchanges and confirms dematerialisation activities and related compliance. The document is a regulatory compliance certificate issued by the Registrar and Share Transfer Agent, not a financial report or announcement of financial results. It does not contain financial statements or management discussion but is a formal attestation related to securities and shareholder records. Given the nature and content, this fits best under Regulatory Filings (RNS), which covers compliance documents and certifications that do not fit other categories.
2025-04-07 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings Classification · 95% confidence The document is a certificate under Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018, for the quarter ended March 31, 2025. It is addressed to stock exchanges and confirms dematerialisation of securities and related compliance. The document is a regulatory compliance certificate rather than a financial report or announcement of financial results. It does not contain financial statements or detailed financial data. The document length is 3281 characters, which is relatively short and focused on certification. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for regulatory compliance documents and certifications that do not fit other specific categories.
2025-04-07 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.